Full Text View
Tabular View
No Study Results Posted
Related Studies
Study to Test the Efficacy and Safety of the Beta-3 Agonist YM178 in Subjects With Symptoms of Overactive Bladder (SCORPIO)
This study has been completed.
First Received: May 29, 2008   Last Updated: April 16, 2009   History of Changes
Sponsor: Astellas Pharma Inc
Information provided by: Astellas Pharma Inc
ClinicalTrials.gov Identifier: NCT00689104
  Purpose

The study is intended to test efficacy, safety and tolerability of two doses of YM178 against placebo and compare the efficacy and safety with active comparator in patients with symptoms of overactive bladder.


Condition Intervention Phase
Urinary Bladder, Overactive
Drug: YM178
Drug: Tolterodine 4 mg
Drug: Placebo
Phase III

Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study
Official Title: A Randomized, Double-Blind, Parallel Group, Placebo and Active Controlled, Multi-Center Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 in Subjects With Symptoms of Overactive Bladder

Resource links provided by NLM:


Further study details as provided by Astellas Pharma Inc:

Primary Outcome Measures:
  • Change from baseline to end of treatment in mean number of micturitions/24 h. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Change from baseline to end of treatment in mean number of incontinence episodes/24 h. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change from baseline in mean volume voided per micturition [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in mean number of urgency incontinence episodes/24 h. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in mean number of urgency episodes (grade 3 and/or 4) /24 h. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Enrollment: 1987
Study Start Date: April 2008
Study Completion Date: March 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Experimental
low dose
Drug: YM178
Oral
2: Experimental
higher dose
Drug: YM178
Oral
3: Active Comparator Drug: Tolterodine 4 mg
Oral
4: Placebo Comparator Drug: Placebo
Oral

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject is willing and able to complete the micturition diary and questionnaires correctly
  • Subject has symptoms of overactive bladder (urinary frequency and urgency with or without urge incontinence) for ≥ 3 months
  • Subject experiences frequency of micturition on average ≥ 8 times per 24-hour period during the 3-day micturition diary period
  • Subject must experience at least 3 episodes of urgency (grade 3 or 4) with or without incontinence, during the 3-day micturition diary period

Exclusion Criteria:

  • Subject is breastfeeding, pregnant, intends to become pregnant during the study, or of childbearing potential, sexually active and not practicing a highly reliable method of birth control
  • Subject has significant stress incontinence or mixed stress/urge incontinence where stress is the predominant factor
  • Subject has an indwelling catheter or practices intermittent self-catheterization
  • Subject has diabetic neuropathy
  • Subject has evidence of a symptomatic urinary tract infection, chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation therapy or previous or current malignant disease of the pelvic organs
  • Subject receives non-drug treatment including electro-stimulation therapy
  • Subject has severe hypertension
  • Subject has a known or suspected hypersensitivity to tolterodine, other anticholinergics, YM178, other ß-AR agonists, or lactose or any of the other inactive ingredients
  • Subject has been treated with any investigational drug or device within 30 days (90 days in the UK)
  • Subject had an average total daily urine volume > 3000 mL as recorded in the 3-day micturition diary period
  • Subject has serum creatinine >150 umol/L, AST and/or ALT > 2x upper limit of normal range (ULN), or γ-GT > 3x ULN
  • Subject has a clinically significant abnormal ECG
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00689104

  Hide Study Locations
Locations
Australia
Auchenflower, Australia
Randwick, Australia
Kogarah, Australia
Clayton, Australia
Woolloongabba, Australia
Austria
Linz, Austria, 4020
Innsbruck, Austria, 6020
Graz, Austria, 8036
Belarus
Minsk, Belarus, 223041
Minsk, Belarus, 220036
Minsk, Belarus, 220119
Belgium
Gent, Belgium, 9000
Liege, Belgium, 4000
Antwerp, Belgium, 2030
Antwerp, Belgium, 2020
Brussels, Belgium, 1090
Brussels, Belgium, 1070
Edegem, Belgium, 2650
Sint Truiden, Belgium, 3800
Leuven, Belgium, 3000
Kortrijk, Belgium, 8500
Leper, Belgium, 8900
Bulgaria
Sofia, Bulgaria
Varna, Bulgaria
Pleven, Bulgaria
Czech Republic
Brno, Czech Republic, 60200
Prague, Czech Republic, 18081
Prague, Czech Republic, 12851
Prague, Czech Republic, 14056
Olomouc, Czech Republic, 77200
Plzen, Czech Republic, 30599
Steti, Czech Republic, 41108
Usti nad Labem, Czech Republic, 40001
Ostrava-Poruba, Czech Republic, 70853
Melnik, Czech Republic, 27601
Denmark
Glostrup, Denmark, 2600
Aalborg, Denmark, 9100
Aarhus, Denmark, 8200
Roskilde, Denmark
Finland
Turku, Finland, 20100
Helsinki, Finland, 00029
Tampere, Finland, 33521
Oulu, Finland, 90220
France
Paris-Cedex 12, France, 75571
Mulhouse, France, 68070
Bordeaux, France, 33076
Nimes Cedex 9, France, 30029
Toulouse Cedex 9, France, 31059
Nantes, France, 45035
Paris, France, 75020
Orleans Cedex 2, France, 45067
Colmar, France, 68024
Marseille Cedex 9, France, 13274
Rouen, France, 76031
Marseille, France, 13285
Strasbourg, France, 67000
Saint Priest en Jarez, France, 42055
Germany
Neustadt i. Sachsen, Germany, 01844
Duisburg, Germany, 47051
Uetersen, Germany, 25436
Koblenz, Germany, 56068
Hamburg, Germany, 20253
Muenchen-Bogenhausen, Germany, 81925
Frankfurt, Germany, 65933
Bautzen, Germany, 02625
Berlin, Germany, 13347
Trier, Germany, 54290
Lutherstadt Eisleben, Germany, 06295
Aichach, Germany, 86551
Bad Ems, Germany, 56130
Ganderkesee, Germany, 27777
Hettstedt, Germany, 06333
Oranienburg, Germany, 16151
Henningsdorf, Germany, 16761
Halle/Saale, Germany, 06132
Radebeul, Germany, 01445
Leipzig, Germany, 04105
Hagenow, Germany, 19230
Sangerhausen, Germany, 06526
Greece
Athens, Greece
Patras, Greece
Thessaloniki, Greece
Nikaias-Piraeus, Greece
Hungary
Debrecen, Hungary, 4043
Papa, Hungary
Budapest, Hungary, 1076
Budapest, Hungary, 1047
Veszprem, Hungary, 8200
Nyiregyhaza, Hungary, 4400
Sopron, Hungary
Szeged, Hungary, 6725
Szekesfehervar, Hungary, 8000
Szekszard, Hungary, 7100
Eger, Hungary, 3300
Budapest, Hungary, 1204
Tatabanya, Hungary, 2800
Iceland
Reykjavik, Iceland, 101
Ireland
Dublin 9, Ireland
Dublin, Ireland
Tralee, Ireland
Cork, Ireland
Mullingar, Ireland
Italy
Varese, Italy, 21100
Florence, Italy, 59129
Milan, Italy, 20142
Latina, Italy, 04100
Catanzaro, Italy, 88100
Modena, Italy, 41100
Milan, Italy, 20153
Genoa, Italy, 16128
Naples, Italy, 80131
Magenta, Italy, 20013
Florence, Italy, 50139
Bari, Italy, 70124
Treviglio, Italy, 24047
Perugia, Italy, 06122
Teramo, Italy, 64100
Latvia
Riga, Latvia
Liepaja, Latvia
Lithuania
Vilnius, Lithuania
Kaunas, Lithuania
Netherlands
Leiden, Netherlands, 2334 CK
Winterswijk, Netherlands, 7101 BN
Enschede, Netherlands, 7511 JX
Apeldoorn, Netherlands
Apeldoorn, Netherlands, 7334 DZ
Tilburg, Netherlands, 5022 GC
Eindhoven, Netherlands, 5623 EJ
Nijmegen, Netherlands, 6532 SZ
Sneek, Netherlands, 8600 BA
Amsterdam, Netherlands, 1105 AZ
Maastricht, Netherlands, 6229 HX
Norway
Drammen, Norway, 3016
Oslo, Norway, 0257
Bergen, Norway, 5021
Tonsberg, Norway, 3103
Hamar, Norway, 2317
Poland
Lodz, Poland, 93-513
Warsaw, Poland, 02-005
Warsaw, Poland, 02-507
Bialystok, Poland, 15-278
Lublin, Poland, 20-954
Chorzow, Poland, 41-500
Lodz, Poland, 93-338
Warsaw, Poland, 00-846
Wroclaw, Poland, 50-556
Portugal
Amadora, Portugal, 2700
Porto, Portugal, 4099-005
Viana do Castelo, Portugal, 4900-858
Tomar, Portugal, 2304-909
Romania
Bucharest, Romania, 22328
Oradea, Romania
Bucharest, Romania
Timisoara, Romania
Lasi, Romania
Russian Federation
St. Petersburg, Russian Federation, 197089
Moscow, Russian Federation, 119435
Moscow, Russian Federation, 105425
Moscow, Russian Federation, 117049
Moscow, Russian Federation, 111020
Moscow, Russian Federation, 101000
St. Petersburg, Russian Federation, 198013
Moscow, Russian Federation, 123836
Moscow, Russian Federation, 117815
Moscow, Russian Federation, 125206
Moscow, Russian Federation, 115516
Moscow, Russian Federation, 111123
Slovakia
Martin, Slovakia, 03659
Zilina, Slovakia, 01207
Poprad, Slovakia, 05801
Skalica, Slovakia, 90982
Trencin, Slovakia, 91101
South Africa
Hatfield, South Africa
Pietermaritzburg, South Africa
Lyttelton, South Africa
Paarl, South Africa
Bloemfontein, South Africa
Spain
Esplugues de Llobregat-Barcelo, Spain, 08950
Madrid, Spain
Barcelona, Spain, 08020
Toledo, Spain, 45071
Villareal, Spain, 12540
Palma de Mallorca, Spain, 07014
Madrid, Spain, 28016
Sevilla, Spain, 41013
Valencia, Spain, 46010
Fuenlabrada, Spain, 28942
Mataro, Spain, 8304
Miranda de Ebro, Spain, 09200
Madrid, Spain, 28046
Bilbao, Spain, 48013
Getafe, Spain, 28905
Sweden
Stockholm, Sweden, 17176
Stockholm, Sweden, 18288
Stockholm, Sweden, 14186
Orebro, Sweden, 70185
Helsingborg, Sweden, 25187
Boras, Sweden, 50182
Uppsala, Sweden, 75185
Umea, Sweden, 90185
Skovde, Sweden, 54130
Stockholm, Sweden, 11883
Switzerland
Luzern, Switzerland, 6000
Frauenfeld, Switzerland, 8501
Ukraine
Kiev, Ukraine, 04053
Kiev, Ukraine, 01023
United Kingdom
Birmingham, United Kingdom, B15 2TG
Sheffield, United Kingdom, S10 2JF
Reading, United Kingdom, RG1 5AN
Newcastle Upon Tyne, United Kingdom, NE7 7DN
London, United Kingdom, W2 2YP
Swansea, United Kingdom, SA6 6NL
Manchester, United Kingdom, M15 6SX
Chorley, United Kingdom, PR7 7NA
London, United Kingdom, SE5 9RS
Northwood, United Kingdom, HA6 2RN
Reading, United Kingdom, RG2 7AG
Croydon, United Kingdom, CR7 7YE
Liverpool, United Kingdom, L22 OLG
Sponsors and Collaborators
Astellas Pharma Inc
Investigators
Study Director: Central Contact Astellas Pharma Europe BV
  More Information

No publications provided

Responsible Party: Astellas Pharma Europe BV ( Disclosure Office Europe )
Study ID Numbers: 178-CL-046, EudraCT number 2007-001451-19
Study First Received: May 29, 2008
Last Updated: April 16, 2009
ClinicalTrials.gov Identifier: NCT00689104     History of Changes
Health Authority: United States: Food and Drug Administration;   Australia: Department of Health and Ageing Therapeutic Goods Administration;   Austria: Federal Office for Safety in Health Care;   Belarus: Ministry of Health;   Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment;   Bulgaria: Bulgarian Drug Agency;   Czech Republic: State Institute for Drug Control;   Denmark: Danish Medicines Agency;   Finland: Finnish Medicines Agency;   France: Afssaps - French Health Products Safety Agency;   Germany: Federal Institute for Drugs and Medical Devices;   Greece: National Organization of Medicines;   Hungary: National Institute of Pharmacy;   Iceland: Icelandic Medicines Control Agency;   Ireland: Irish Medicines Board;   Italy: Ethics Committee;   Latvia: State Agency of Medicines;   Lithuania: State Medicine Control Agency - Ministry of Health;   Netherlands: The Central Committee on Research Involving Human Subjects (CCMO);   Norway: Norwegian Medicines Agency;   Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products;   Portugal: National Pharmacy and Medicines Institute;   Romania: National Medicines Agency;   Russia: Ministry of Health and Social Development of the Russian Federation;   Slovakia: State Institute for Drug Control;   South Africa: Medicines Control Council;   Spain: Spanish Agency of Medicines;   Sweden: Medical Products Agency;   Switzerland: Swissmedic;   Ukraine: Ministry of Health;   United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Astellas Pharma Inc:
Overactive bladder (OAB)
Frequency
Micturition
Urgency
Urinary incontinence
Urinary urge incontinence
YM178

Additional relevant MeSH terms:
Urinary Bladder, Overactive
Neurotransmitter Agents
Cholinergic Antagonists
Molecular Mechanisms of Pharmacological Action
Urinary Bladder Diseases
Physiological Effects of Drugs
Cholinergic Agents
Pharmacologic Actions
Muscarinic Antagonists
Urological Manifestations
Signs and Symptoms
Urologic Diseases
Tolterodine

ClinicalTrials.gov processed this record on November 27, 2009